Natco, Hetero Get DCGI Nod to Sell Hep-C Drug

Published: 15th December 2015 03:31 AM  |   Last Updated: 15th December 2015 03:31 AM   |  A+A-

HYDERABAD: Two city-based drug makers Natco Pharma and Hetero said they received approval from the Drugs  Controller General of India (DCGI) to sell generic version of Daclatasvir, used for the treatment of chronic hepatitis C.

“It is the first company in India to get approval for generic Daclatasvir Dihydrochloride (Daclatasvir) tablets, 30 mg & 60 mg, from the Drugs Controller General (India),” Natco said in a disclosure with the bourses.

Daclatasvir is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection.

“The company has received the approval from Drug Controller General of India for the generic version of Daclatasvir tablets in the strengths of 30 mg and 60 mg,” Hetero said.

Natco said it will launch immediately in India at `6,000 and `4,000 for the 60 mg and 30 mg strengths, respectively, for a bottle of 28 tablets.

“Compared with other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patients subsets,” Natco said adding that it will market generic Daclatasvir under its own brand ‘NATDAC,’ and through its strategic partners in India.

Hetero said its product was a generic version of Bristol-Myers Squibb’s Daklinza tablets. It has over 25 manufacturing facilities worldwide and its portfolio includes over 200 products in therapeutic categories like HIV/AIDS, cardiovascular, oncology, neurology and hepatitis.

Meanwhile, Natco said and its partner Alvogen settled a patent infringement suit with Gilead Sciences Inc and others over Tamiflu in a US court.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp